Source-grounded facts extracted from ACADIA PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ACADIA PHARMACEUTICALS INC shareholders approved Approval of amendment to the Plan to increase authorized shares by 5,209,670 shares at the 2026-05-29 meeting.
“the approval of an amendment to the Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the Plan by 5,209,670 shares, which was approved by the following vote: For Against Abstain Broker Non-Votes 147,258,860 3,096,136 93,751 10,356,394”
ACADIA PHARMACEUTICALS INC shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-29 meeting.
“the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote: For Against Abstain 157,409,378 3,319,736 76,027”
ACADIA PHARMACEUTICALS INC shareholders approved Advisory approval of named executive officer compensation at the 2026-05-29 meeting.
“the approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, which was approved by the following vote: For Against Abstain Broker Non-Votes 148,265,173 1,911,358 272,216 10,356,394”
ACADIA PHARMACEUTICALS INC shareholders approved Election of three Class I directors at the 2026-05-29 meeting.
“The following three Class I directors were elected by the votes indicated: For Withheld Broker Non-Votes James M. Daly 146,927,745 3,521,002 10,356,394 Edmund P. Harrigan, M.D. 128,460,130 21,988,617 10,356,394 Adora Ndu, Pharm.D., J.D. 134,540,552 15,908,195 10,356,394”
ACADIA PHARMACEUTICALS INC reported the first quarter ended March 31, 2026 results: revenue total revenues of $268 million. Guidance reaffirmed.
“Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm”
Elizabeth H.Z. Thompson retired as Head of Research and Development at ACADIA PHARMACEUTICALS INC.
“On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.”
ACADIA PHARMACEUTICALS INC: Amended and restated bylaws adopted, including changes to stockholder meeting procedures, director nomination requirements, quorum and voting thresholds, and indemnification provisions (effective 2025-04-15).
“On April 15, 2025, the board of directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”) effective as of such adoption date.”
ACADIA PHARMACEUTICALS INC completed a disposition for $150.0 million (closed 2024-12-11).
“10-Q for the period ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024. Pursuant to the PRV Transfer Agreement, the Company received $150.0 million upon the closing of the Asset Sale. Pursuant to the Joint Venture and License Agreement, dated July 13, 2023, with Neuren Pharmaceuticals Limited (Neuren), one third of the net”
Brendan Teehan departed as Executive Vice President, Chief Operating Officer and Head of Commercial at ACADIA PHARMACEUTICALS INC.
“On November 18, 2024, Acadia Pharmaceuticals Inc. (the “Company”) agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company’s Management Severance Benefit Plan (the “Severance Plan”)) from his position, effective immediately.”
Catherine Owen Adams was appointed as Chief Executive Officer at ACADIA PHARMACEUTICALS INC.
“On September 20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the “principal executive officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date.”
Stephen R. Davis was terminated as President and Chief Executive Officer at ACADIA PHARMACEUTICALS INC.
“Stephen R. Davis is departing the Company and will be succeeded by Catherine Owen Adams.”
ACADIA PHARMACEUTICALS INC reported financial results for the three months ended March 31, 2024.
“On May 8, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2024.”
ACADIA PHARMACEUTICALS INC updated its Full Year 2024 guidance (initiated).
“Full Year 2024 Financial Guidance • DAYBUE net product sales in the range of $370 to $420 million. • NUPLAZID net product sales in the range of $560 to $590 million. • GAAP R&D expense in the range of $305 to $325 million. • GAAP SG&A expense in the range of $455 to $480 million.”
ACADIA PHARMACEUTICALS INC reported fourth quarter and full year ended December 31, 2023 results: revenue $231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023, net income net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023, EPS $0.28 per common share for the fourth quarter and $(0.37) per common share for the full year.
“Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.”
Austin D. Kim resigned as Executive Vice President, General Counsel and Secretary at ACADIA PHARMACEUTICALS INC.
“On January 30, 2024, Acadia Pharmaceuticals Inc. (the “Company”) announced that Austin D. Kim, Executive Vice President, General Counsel and Secretary, will be leaving the Company to pursue other opportunities.”
ACADIA PHARMACEUTICALS INC reported the nine months ended September 30, 2023 results: revenue $495.4 million, net income $107.1 million, EPS $0.65 per common share. Guidance initiated.
“and were $495.4 million for the nine months ended September 30, 2023”
ACADIA PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $211.7 million, net income $65.2 million, EPS $0.40 per common share. Guidance initiated.
“Total revenues, comprised of net product sales from NUPLAZID and DAYBUE were $211.7 million for the three months ended September 30, 2023”
ACADIA PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $283.7 million, net income a net loss of $41.9 million, or $0.26 per common share, EPS $0.26 per common share.
“Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023, and were $283.7 million for the six months ended June 30, 2023.”
ACADIA PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $165.2 million, net income $1.1 million, or $0.01 per common share, EPS $0.01 per common share.
“Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023”
ACADIA PHARMACEUTICALS INC reported second quarter of 2023 results: revenue $140 to $144 million. Guidance reaffirmed.
“DAYBUE 2Q 2023 preliminary net sales: $21 to $23 million.”
ACADIA PHARMACEUTICALS INC entered into Joint Venture and License Agreement with Neuren Pharmaceuticals Limited valued at upfront payment $100.0 million; milestone payments up to $405.0 million per product; tiered double-d (effective 2023-07-13).
“On July 13, 2023, Acadia Pharmaceuticals Inc. (the “Company”) and Neuren Pharmaceuticals Limited (“Neuren”) entered into a joint venture and license agreement (the “License Agreement”) for the global commercialization and development of trofinetide and of Neuren’s development candidate NNZ-2591.”
ACADIA PHARMACEUTICALS INC shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
“the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the following vote: For Against Abstain 144,928,829 466,591 136,938”
ACADIA PHARMACEUTICALS INC shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-06-01 meeting.
“the indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, which received the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 135,140,475 54,863 345,208 111,380 9,880,432”
ACADIA PHARMACEUTICALS INC shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-01 meeting.
“the approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 1, 2023, which was approved by the following vote: For Against Abstain Broker Non-Votes 87,274,917 48,257,939 119,071 9,880,431”
ACADIA PHARMACEUTICALS INC shareholders approved Election of three Class I directors at the 2023-06-01 meeting.
“The following three Class I directors were elected by the votes indicated: For Withheld Broker Non- Votes James M. Daly 108,235,140 27,416,787 9,880,431 Edmund P. Harrigan 126,226,342 9,425,585 9,880,431 Adora Ndu 131,558,098 4,093,829 9,880,431”
ACADIA PHARMACEUTICALS INC reported three months ended March 31, 2023 results: revenue $118.5 million, net income $43.0 million, or $0.27 per common share, EPS $0.27 per common share. Guidance reaffirmed.
“language. --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID ® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUETM (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 -”
ACADIA PHARMACEUTICALS INC reported financial results for the full year ended December 31, 2022.
“On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.”
ACADIA PHARMACEUTICALS INC reported financial results for the fourth quarter ended December 31, 2022.
“On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.”
ACADIA PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $130.7 million, net income $(0.17) per common share, EPS $(0.17) per common share. Guidance lowered.
“Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022. NUPLAZID delivered net sales of $130.7 million in the third quarter of 2022”
Srdjan R. Stankovic departed as President at ACADIA PHARMACEUTICALS INC.
“On October 27, 2022, Srdjan R. Stankovic, M.D., M.S.P.H., notified Acadia Pharmaceuticals Inc. (the “Company”) of his intention to retire as the Company’s President, effective December 31, 2022.”
Adora Ndu was appointed as Director at ACADIA PHARMACEUTICALS INC.
“appointed Adora Ndu, Pharm.D., J.D. as a director to fill the newly created vacancy.”
Mark C. Schneyer was appointed as Executive Vice President, Chief Financial Officer at ACADIA PHARMACEUTICALS INC.
“On December 9, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Mark C. Schneyer as Executive Vice President, Chief Financial Officer.”
Brendan P. Teehan was appointed as Executive Vice President, Chief Operating Officer and Head of Commercial at ACADIA PHARMACEUTICALS INC.
“On November 1, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Brendan P. Teehan as Executive Vice President, Chief Operating Officer and Head of Commercial and as the Company’s principal operating officer.”
Mark Schneyer was appointed as interim Chief Financial Officer at ACADIA PHARMACEUTICALS INC.
“The Board also appointed Mark Schneyer as the Company’s interim Chief Financial Officer.”
Stephen Davis was appointed as principal financial officer at ACADIA PHARMACEUTICALS INC.
“On August 31, 2021, the Board of Directors of the Company (the “Board”) appointed Stephen Davis, the Company’s Chief Executive Officer, as the Company’s principal financial officer.”
Elena Ridloff resigned as Executive Vice President and Chief Financial Officer at ACADIA PHARMACEUTICALS INC.
“Elena Ridloff gave notice on August 30, 2021 of her resignation as Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc. (the “Company”), effective September 10, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.